FPH Stock Overview
Designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fisher & Paykel Healthcare Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$35.05 |
| 52 Week High | NZ$35.76 |
| 52 Week Low | NZ$20.18 |
| Beta | 0.39 |
| 11 Month Change | 5.26% |
| 3 Month Change | 8.21% |
| 1 Year Change | 73.17% |
| 33 Year Change | 10.99% |
| 5 Year Change | 68.19% |
| Change since IPO | 1,342.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| FPH | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 2.5% | 1.8% | 1.2% |
| 1Y | 73.2% | 16.1% | 19.7% |
Return vs Industry: FPH exceeded the Australian Medical Equipment industry which returned 14.8% over the past year.
Return vs Market: FPH exceeded the Australian Market which returned 18.4% over the past year.
Price Volatility
| FPH volatility | |
|---|---|
| FPH Average Weekly Movement | 3.3% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: FPH has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: FPH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1934 | 7,005 | Lewis Gradon | www.fphcare.com |
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation.
Fisher & Paykel Healthcare Corporation Limited Fundamentals Summary
| FPH fundamental statistics | |
|---|---|
| Market cap | AU$20.66b |
| Earnings (TTM) | AU$119.19m |
| Revenue (TTM) | AU$1.57b |
173.3x
P/E Ratio13.2x
P/S RatioIs FPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FPH income statement (TTM) | |
|---|---|
| Revenue | NZ$1.74b |
| Cost of Revenue | NZ$698.40m |
| Gross Profit | NZ$1.04b |
| Other Expenses | NZ$911.80m |
| Earnings | NZ$132.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 59.93% |
| Net Profit Margin | 7.61% |
| Debt/Equity Ratio | 6.5% |
How did FPH perform over the long term?
See historical performance and comparison